Drug name - Mekinist
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(4 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(8 years from now) | |
| CN101912400A | NOVARTIS | 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer |
Jun, 2025
(2 years from now) | |
| CN101006086A | NOVARTIS | 5-Amido-2, 4, 7-Trioxy-3, 4, 7, 8-Tetrahydropyranyl Ether-2H-Naphthyridine [2,3-D] Pyrimidine Derivatives And Correlative Compound Used For Curing Cancer |
Jun, 2025
(2 years from now) | |
| CN101912400B | NOVARTIS | 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer |
Jun, 2025
(2 years from now) | |
| CN101006086B | NOVARTIS | For The 5 - -2, 4, 7 - -3, 4, 7, 8-Tetrahydro - -2H - Pyrido [2, 3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer |
Jun, 2025
(2 years from now) | |
| CN102655753A | NOVARTIS | Combination |
Oct, 2030
(8 years from now) | |
| CN102655753B | NOVARTIS | Combined Medicine |
Oct, 2030
(8 years from now) | |
| IN200700102P4 | NOVARTIS | Pyrimidine Compound And Medical Use Thereof |
Jun, 2025
(2 years from now) | |
| IN237689B | NOVARTIS | 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyridio[2,3-D]Pyrimidine Derivatives And A Pharmaceutical Composition Comprising The Same |
Jun, 2025
(2 years from now) | |
| EP2298768B9 | NOVARTIS | 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer |
Jun, 2025
(2 years from now) | |
| EP2298768B1 | NOVARTIS | 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer |
Jun, 2025
(2 years from now) | |
| EP2298768A1 | NOVARTIS | 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer |
Jun, 2025
(2 years from now) | |
| EP1761528A1 | NOVARTIS | 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer |
Jun, 2025
(2 years from now) | |
| EP1761528B1 | NOVARTIS | 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer |
Jun, 2025
(2 years from now) | |
| EP2488033A1 | NOVARTIS | Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor |
Oct, 2030
(8 years from now) | |
| EP2488033B1 | NOVARTIS | Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor |
Oct, 2030
(8 years from now) | |
| EP2488033A4 | NOVARTIS | Combination |
Oct, 2030
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(2 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(8 years from now) | |
| US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
| US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
| US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
| US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(9 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(10 years from now) | |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; treatment of unresectable or metastatic melanoma; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; in combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.5MG | TABLET;ORAL | Prescription |
| EQ 1MG | TABLET;ORAL | Discontinued |
| EQ 2MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.